Literature DB >> 9072844

[Primary radiotherapy of laryngeal carcinoma. An analysis of the therapeutic results and of the the relapse behavior in 283 patients].

C Rübe1, O Micke, G Grevers, R Rohloff, H Kaufmann, M Busch, N Willich.   

Abstract

PURPOSE: In the treatment of laryngeal carcinoma definitive radiotherapy results in a similar outcome as surgical treatment in the early stages with a lower morbidity rate and good functional results. In fact no randomized studies exist, so far, and the optimal treatment concept for the different stages is not well defined. The following study analyses retrospectively the treatment results and the recurrence data in patients with a squamous cell carcinoma of the larynx treated with definitive radiotherapy. PATIENTS AND
METHOD: Two hundreds and eighty-three patients with carcinoma of the larynx were treated with radiation therapy in the department of radiology of the LMU München between September 1971 and June 1986. Twenty-six patients (9.2%) were female and 257 (73.1%) male. The median age was 68.5 years, respectively 70 years. All patients had a histologically confirmed squamous cell carcinoma of the larynx. No true subglottic cases were observed. Forty-one (14.5%) tumors were localized supraglottically, 207 (73.1%) glottically. Thirty-five patients had a T4 tumor with glottic and supraglottic involvement. In 147 patients the histopathological grading was evaluable: 32 tumors were classified as G1, 95 as G2, 15 as G3 and 5 as G4. According to the UICC classification of 1979 25 patients had a carcinoma in situ (Tis), 93 patients had a stage T1, 90 stage T2, 40 stage T3 and 35 stage T4. Two hundreds and thirty-three of 283 (82.3%) had no lymph node involvement. In 50 patients clinically a lymph node involvement was observed. 22 patients had a stage N1, 5 patients stage N2 and 23 patients stage N3. An external beam radiation mostly with cobalt-60 was performed with a mean dose of 61.9 Gy.
RESULTS: The 5-years relapse-free survival for the whole group was 61.7%. The probability for "no evidence of disease" (NED) depended on tumor stage and localisation (glottic tumors: Tis/T1 90.5%: T2 59.4%: T3 39.6%: [5-year NED]; supraglottic tumors T1 64.2%: T2/3 28.6%: T4/N3 24.7% [3-year NED]). Other significant prognostic factors besides T-stage were N-stage (NO vs. N1-3: 3-year recurrence-free survival 68% vs. 37.2%, p < 0.001) and histopathologic grading (G1 vs. G3/4: 3-year recurrence-free survival 74% vs. 37.1%, p < 0.01). One hundred and twenty-two (43.1%) patients had a recurrence, which occurred in 75.4% local, in 12.3% loco regional, in 8.2%, with distant metastases and 4.1% combined. In 50 patients with a recurrent disease a salvage therapy was carried out. Thereby 17 patients achieved a complete response.
CONCLUSION: Even for the here described negatively selected patient group with a high median age and multimorbidity, good local control rates could be achieved especially in early stages with definitive radiation therapy. In more advanced stages even in elderly patients a combined surgical-radiotherapeutic treatment should be performed.

Entities:  

Mesh:

Year:  1997        PMID: 9072844     DOI: 10.1007/bf03038927

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  26 in total

1.  Stage T3 squamous cell carcinoma of the glottic larynx: a comparison of laryngectomy and irradiation.

Authors:  W M Mendenhall; J T Parsons; S P Stringer; N J Cassisi; R R Million
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  Radiation therapy for advanced (T3T4N0-N3M0) laryngeal carcinoma: the need for a change of strategy: a radiotherapeutic viewpoint.

Authors:  A B Karim; J H Kralendonk; K H Njo; A H Tierie; A Hasman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-11       Impact factor: 7.038

3.  Analysis of surgical therapy for epidermoid carcinoma of the laryngeal glottis.

Authors:  J H Ogura; D G Sessions; G J Spector
Journal:  Laryngoscope       Date:  1975-09       Impact factor: 3.325

4.  Work-related risk factors for laryngeal cancer.

Authors:  W D Flanders; C I Cann; K J Rothman; M P Fried
Journal:  Am J Epidemiol       Date:  1984-01       Impact factor: 4.897

5.  Stage II glottic carcinoma: prognostic factors and management.

Authors:  M J Kaplan; M E Johns; W C McLean; G S Fitz-Hugh; D A Clark; J C Boyd; R W Cantrell
Journal:  Laryngoscope       Date:  1983-06       Impact factor: 3.325

6.  [Treatment results of radiotherapy of T1-4N0M0 laryngeal cancer from 1963 to 1982].

Authors:  U Weischedel; C Wieland
Journal:  Strahlenther Onkol       Date:  1986-07       Impact factor: 3.621

7.  Twice-a-day radiation therapy for supraglottic carcinoma.

Authors:  C C Wang; H D Suit; P H Blitzer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-01       Impact factor: 7.038

8.  The primary treatment of advanced vocal cord cancer: laryngectomy or radiotherapy?

Authors:  W van den Bogaert; F Ostyn; E van der Schueren
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-03       Impact factor: 7.038

9.  T1-T2 vocal cord carcinoma: a basis for comparing the results of radiotherapy and surgery.

Authors:  W M Mendenhall; J T Parsons; S P Stringer; N J Cassisi; R R Million
Journal:  Head Neck Surg       Date:  1988 Jul-Aug

10.  The Patterns of Care Outcome Studies: results of the National practice in carcinoma of the larynx.

Authors:  R A Lustig; C J MacLean; G E Hanks; S Kramer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-12       Impact factor: 7.038

View more
  3 in total

1.  Treatment and predictive factors in patients with recurrent laryngeal carcinoma: A retrospective study.

Authors:  Peijing Li; Weihan Hu; Yuan Zhu; Jianjiang Liu
Journal:  Oncol Lett       Date:  2015-08-25       Impact factor: 2.967

2.  Management of the N0 neck in recurrent laryngeal squamous cell carcinoma.

Authors:  Pei-Jing Li; Wei-Han Hu; Ting Jin
Journal:  Mol Clin Oncol       Date:  2015-10-29

3.  LOH detected by microsatellite markers reveals the clonal origin of recurrent laryngeal squamous cell carcinoma.

Authors:  Zhaoyang Cui; Xinliang Pan; Qirong Wang
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.